Burgon, Patrick


Patrick Burgon, PhD, is a Scientist  and Director of the Molecular Singaling Laboratory at the University of Ottawa Heart Institute. He is also an Assistant Professor of Medicine (Cardiology) and Assistant Professor at the Department of Cellular and Molecular Medicine, University of Ottawa. He is a Member of the Faculty of Graduate and Post-doctoral Studies at the University of Ottawa.


Dr. Burgon earned a BAppSc degree in Biochemistry and Microbiology in 1989 from the Royal Melbourne Institute of Technology and a PhD degree in 1996 from Monash University, Melbourne, Australia. Dr. Burgon received his post-doctoral training at Harvard University and Harvard Medical School, initially under Drs. Ernest Peralta and Eva Neer (regulation of G protein coupled receptor signalling), and then under Dr. Christine Seidman and Dr. Jon Seidman (cardiovascular signalling). Dr. Burgon joined the University of Ottawa Heart Institute in 2005.

Dr. Burgon acts as a peer reviewer for the Canadian Institutes of Health Research (CIHR), (2014 – current: College of Reviewers; 2012- current: Peer Review Committee Cardiovascular Science A), and previously for the Heart and Stroke Foundation (HSFC) (Peer Review Committee IVa). He is currently (since 2014) the Co-Chair of the American Heart Association Cardiovascular Development BSc1 Study Section. He has been on the organizing committees of international conferences such as the Ottawa Heart Research Conference and the Canadian Cardiology Congress. Dr. Burgon has acted as a reviewer (ad hoc) for Journal of Biological Chemistry, Circulation Research, PNAS and American Journal of Physiology.

Dr. Burgon was a finalist in the 2013 Eric Olson Orations in Cardiovascular Science from the International Academy of Cardiovascular Sciences. He was awarded the Top 5 Abstract from Canada, at the 2011 American Heart Association conference. Dr. Burgon has patented his Muscle Lamin A/C Interacting Protein in the United States (Patent Appln No. 60/956,533).

Research & Clinical Interests 

The genetic determinants of heart development and disease have focused on early fetal heart formation and the pathogenesis of childhood and adult heart disease. During this time, the myocardium undergoes a period of hyperplastic growth that causes a huge increase in the number of cardiomyocytes that make up the adult heart. Soon after birth, cardiomyocytes stop dividing and all subsequent increases in myocardial mass is done by cardiomyocyte hypertrophy. Despite the importance of this phenomenon, little is known about the molecular basis for the transition from hyperplastic to hypertrophic-based myocardial growth during normal perinatal cardiac development. Dr. Burgon’s laboratory is interested in understanding the mechanisms involved in this transition.


See current publications list at PubMed.

Selected publications:

  1. Jiang J*, Burgon PG*, Wakimoto H*, Onoue K*, O’Meara C, Fomovsky G, McConnell BK, Lee RT, Seidman JG and Seidman CE. Cardiac Myosin Binding Protein C Regulates Postnatal Myocyte Cytokinesis. 2015 PNAS (In Press) *equal contribution
  2. Burgon, PG*, Human genome organization-symbolized muscle-enriched a-type lamin-interacting protein to clear up confusion. Circ Res. 2012 Oct 12;111(9):e252.
  3. Ahmady E, Deeke SA, Rabaa S, Kouri L, Kenney L, Stewart AF, Burgon PG. Identification of a novel muscle enriched A-type lamin interacting protein (MLIP). Journal of Biological Chemistry. 2011; 286(22): 19702-13.
  4. King JC, Moskowitz IP, Burgon PG, Ahmad F, Stone JR, Seidman JG, Lees JA. E2F3 plays an essential role in cardiac development and function. Cell Cycle. 2008 Dec 22;7(23).
  5. Burgon PG, Lee WL, Nixon AB, Peralta EG, Casey PJ.  Phosphorylation and nuclear translocation of a Regulator of G-protein Signaling (RGS10).  Journal of Biological Chemistry. 2001; 276 (35): 32828-34

Share This